Our study suggests that the targeted inhibition of IL6 or MARCH3 could reduce the development of OSA‐induced NAFLD, providing new ideas for the prevention and treatment of OSA‐related NAFLD. Here, MARCHF3 is linked to metabolic dysfunction-associated steatotic liver disease.